Neuromyelitis optica spectrum disorders: Comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands

European Journal of Neurology

Volumn 23, Issue 3, 2016, Pages 580-587

  van Pelt, E D ^a   Wong, Y Y M ^a   Ketelslegers, I A ^a   Hamann, D ^b   Hintzen, R Q ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Sanquin Diagnostiek   (Netherlands)

Author keywords

AQP4 IgG; MOG IgG; Neuromyelitis optica; NMO spectrum disorders

Indexed keywords

AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; IMMUNOGLOBULIN G; MITOXANTRONE; MYCOPHENOLIC ACID; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PREDNISONE; RITUXIMAB; AQP4 PROTEIN, HUMAN; AUTOANTIBODY; MOG PROTEIN, HUMAN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CAUCASIAN; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; HUMAN; HUMAN CELL; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELITIS; MYELOOPTIC NEUROPATHY; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; BLOOD; IMMUNOLOGY; MIDDLE AGED; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; AQUAPORIN 4; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; MYELITIS, TRANSVERSE; NETHERLANDS; NEUROMYELITIS OPTICA; OPTIC NEURITIS;

EID: 84959553221     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12898     Document Type: Article

References (23)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
2. McKeon A, Fryer JP, Apiwattanakul M, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 2009; 66: 1134-1138.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
4. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
5. Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ. Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Mult Scler 2011; 17: 1527-1530.
6. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8: 184.
7. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71: 276-283.
8. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012; 79: 1273-1277.
9. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474-481.
10. Höftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2014; 21: 866-874.
11. Tanaka M, Tanaka K. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol 2014; 270: 98-99.
12. Probstel AK, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation 2015; 12: 46.
13. Waters P, Woodhall M, O'Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015; 2: e89.
14. Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2014; 1: e40.
15. Nakajima H, Motomura M, Tanaka K, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open 2015; 5: e007766.
16. Martinez-Hernandez E, Sepulveda M, Rostasy K, et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor alpha1 subunit in patients with isolated optic neuritis. JAMA Neurol 2015; 72: 187-193.
17. Ketelslegers IA, Van Pelt DE, Bryde S, et al. Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler J 2015; 21: 1513-1520.
18. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013; 9: 455-461.
19. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
21. Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015; 84: 1165-1173.
22. Bernard-Valnet R, Liblau RS, Vukusic S, Marignier R. Neuromyelitis optica: a positive appraisal of seronegative cases. Eur J Neurol 2015. doi:10.1111/ene.12679.
23. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015; 2: e62.